Global Central Nervous System Biomarkers Market - 2023-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	195 Pages	DataM Intelligence 4Market Research LLP	June, 2023	DTAM18000972

Best Price Guarantee
Price	from $4,350
Length	195 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	June, 2023
SKU	DTAM18000972

Global Central Nervous System Biomarkers Market - 2023-2030

The Global Central Nervous System Biomarkers Market size reached US$ 4,790.8 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 9,852.7 million by 2030. The market is exhibiting at a CAGR of 9.7% during the forecast period (2023-2030).

Biomarkers or biological markers are quantitative measurements that provide information about biological processes, a disease state, or a response to treatment. They have the potential to better understand the etiology and pathogenesis of a given disorder, providing researchers and clinicians with valuable insight into diagnosis, treatment, and prognosis for many debilitating disorders and diseases.

The central nervous system biomarkers market is driven by factors such as combining proteomics, genomics, and metabolomic interrogation of CNS tissues, CSF, or blood, and imaging technologies and the development of novel biomarkers.

Market Dynamics

Increasing Demand For Novel Biomarkers

Novel potential biomarkers for CNS disorders include the tau protein, neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase-L1 (UCH-L1). The tau protein is a neuroaxonal marker located mainly in the white matter of the central nervous system and is reported to be increased in ischemic stroke and cardiac arrest. The NFL is highly accurate in prognostication after cardiac arrest, but it has also been reported to increase in neurodegenerative disorders such as Alzheimer's disease.

GFAP is an astrocytic marker that is produced as part of a neuroprotective mechanism and has been associated with prognosis after head trauma, intracerebral hemorrhage, ischemic stroke, and cardiac arrest. UCH-L1 is a neuronal cell body marker that is crucial for neuroaxonal stability and repair after brain injury.

Technological advances have increased the pace of biomarker discovery, but most are yet to be validated. Incorporating biomarkers into clinical trials and practice will help improve study efficiency and inform advancements in personalized neurology.

High Cost of CNS Biomarker Testing and Diagnostics

With the high cost of the validation process, such as sample collection & storage, government rules and policies are changing since reimbursements do not cover biomarker-mediated therapies that are not considered standard of care.

Even though biomarkers add significant value to tests, refunds are limited. For instance, Medicare, the nation's largest healthcare insurer with more than 50 million beneficiaries, does not fund experimental medicines or most screening and biomarker tests. Therefore, the above factors are expected to hamper the market growth over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has been linked to a range of neurological complications, including cognitive impairment and neurodegenerative changes. For instance, Marshall University, West Virginia, reviewed the diverse neurodegenerative changes associated with COVID-19 and highlighted the importance of major circulating biomarkers, associated with disease progression and severity.

Their literature survey indicated that important CNS proteins, such as GFAP, NfL, and pT181-tau, and various inflammatory cytokines, are altered significantly in COVID-19 patients. The current understanding of the neuropathological changes associated with COVID-19 and the potential use of biomarkers in identifying patients at risk for developing severe forms of the disease is limited.

Russia-Ukraine Conflict Analysis

Risk about the war's long-term impact on the scientific community worldwide and the missed opportunities for research in Ukraine's academic, medical, and scientific disciplines during Russia Ukraine war. Ukraine was testing 251 medicines and devices, according to the FDA's clinical trials database.

According to the clinical trials database, in 2022, over 1,000 medication clinical trials were underway or planned in Ukraine, including 786 in the field of oncology alone. The war has had a negative impact on Russian clinical trial sites, as resources and manpower are not allocated according to priority, leading to worsening CNS care.

Segment Analysis

The global central nervous system biomarkers market is segmented by type, application, disease, end-user, and by region

Based on Type, Safety Biomarkers Segment Is Expected To Drive The Market Growth

The safety biomarkers segment accounted for the highest market stake accounting for approximately 35.5% of the central nervous system biomarkers market in 2022. Safety biomarkers are expected to dominate the market growth due to increased awareness of health issues such as depression, Parkinson's, and multiple sclerosis. They play a crucial role in preclinical and clinical research trials, with rapid changes in growth measurement, computation, and analysis leading to the explosive growth of the translational research field. For Instance, Donanemab improved cognition and ability to perform activities of daily living in patients with early Alzheimer's disease at 76 weeks.

Geographical Analysis

The Rising CNS Cancer Cases And Increasing R&D Expenditure

North America is estimated to hold around 42.7% of the total market share throughout the forecast period due to rising CNS cancer cases and increased R&D expenditure. According to the American Cancer Society, brain malignancy is the second most common cancer in children and adolescents, where CNS biomarkers are commonly used.

Competitive Landscape

The major global players in the market include Acumen Pharmaceuticals, Biogen, Alseres Pharmaceuticals, Aposense, Avacta Life Sciences Ltd., Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., DiaGenic ASA, G-Biosciences, and Thermo Fisher Scientific.

Why Purchase the Report?
• To visualize the global central nervous system biomarkers market segmentation based on type, application, disease, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of central nervous system biomarkers market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global central nervous system biomarkers market report would provide approximately 54 tables, 46 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary: 3.1. Snippet by Type; 3.2. Snippet by Application; 3.3. Snippet by Disease; 3.4. Snippet by End-User; 3.5. Snippet by Region
4. Dynamics: 4.1. Impacting Factors; 4.1.1. Drivers; 4.1.1.1. Increasing demand for Novel Biomarkers; 4.1.2. Restraints; 4.1.2.1. High Cost of CNS Biomarker Testing and Diagnostics; 4.1.3. Opportunity; 4.1.4. Impact Analysis
5. Industry Analysis: 5.1. Porter's 5 Forces Analysis; 5.2. Supply Chain Analysis; 5.3. Pricing Analysis; 5.4. Regulatory Analysis
6. COVID-19 Analysis: 6.1. Analysis of COVID-19; 6.1.1. Scenario Before COVID-19; 6.1.2. Scenario During COVID-19; 6.1.3. Scenario Post COVID-19; 6.2. Pricing Dynamics Amid COVID-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During the Pandemic; 6.5. Manufacturer’s Strategic Initiatives; 6.6. Conclusion
7. By Type: 7.1. Introduction; 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 7.1.2. Market Attractiveness Index, By Type; 7.2. Safety Biomarkers*; 7.2.1. Introduction; 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 7.3. Efficacy Biomarkers; 7.4. Validation Biomarkers; 7.5. Others
8. By Application: 8.1. Introduction; 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application; 8.1.2. Market Attractiveness Index, By Application; 8.2. Drug Discovery & Development*; 8.2.1. Introduction; 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 8.3. Personalized Medicines; 8.4. Disease Risk Assessment; 8.5. Diagnostics; 8.6. Others
9. By Disease: 9.1. Introduction; 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease; 9.1.2. Market Attractiveness Index, By Disease; 9.2. Multiple Sclerosis*; 9.3. Alzheimer's Disease; 9.4. Parkinson's Disease; 9.5. Traumatic Brain Injury; 9.6. Others
10. By End-User: 10.1. Introduction; 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 10.1.2. Market Attractiveness Index, By End-User; 10.2. Diagnostic Labs; 10.3. Clinics; 10.4. Hospitals; 10.5. Research Centers; 10.6. Others
11. By Region: 11.1. Introduction; 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 11.1.2. Market Attractiveness Index, By Region; 11.2. North America; 11.2.1. Introduction; 11.2.2. Key Region-Specific Dynamics; 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application; 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease; 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 11.2.7.1. The U.S.; 11.2.7.2. Canada; 11.2.7.3. Mexico; 11.3. Europe; 11.3.1. Introduction; 11.3.2. Key Region-Specific Dynamics; 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application; 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease; 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 11.3.7.1. Germany; 11.3.7.2. The U.K.; 11.3.7.3. France; 11.3.7.4. Italy; 11.3.7.5. Spain; 11.3.7.6. Rest of Europe; 11.4. South America; 11.4.1. Introduction; 11.4.2. Key Region-Specific Dynamics; 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application; 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease; 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 11.4.7.1. Brazil; 11.4.7.2. Argentina; 11.4.7.3. Rest of South America; 11.5. Asia-Pacific; 11.5.1. Introduction; 11.5.2. Key Region-Specific Dynamics; 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application; 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease; 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 11.5.8. China; 11.5.9. India; 11.5.10. Japan; 11.5.11. Australia; 11.5.12. Rest of Asia-Pacific; 11.6. Middle East and Africa; 11.6.1. Introduction; 11.6.2. Key Region-Specific Dynamics; 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application; 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease; 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape: 12.1. Competitive Scenario; 12.2. Market Positioning/Share Analysis; 12.3. Mergers and Acquisitions Analysis
13. Company Profiles: 13.1. Acumen Pharmaceuticals Inc.*; 13.1.1. Company Overview; 13.1.2. Product Portfolio and Description; 13.1.3. Financial Overview; 13.1.4. Key Developments; 13.2. Biogen Inc.; 13.3. Alseres Pharmaceuticals Inc.; 13.4. Aposense Ltd.; 13.5. Avacta Life Sciences Ltd.; 13.6. Banyan Biomarkers Inc.; 13.7. Bio-Rad Laboratories Inc.; 13.8. DiaGenic ASA; 13.9. G-Biosciences; 13.10. Thermo Fisher Scientific Inc.; LIST NOT EXHAUSTIVE
14. Appendix: 14.1. About Us and Services; 14.2. Contact Us